Regeneron’s DB-OTO: Overcoming Clinical and Manufacturing Hurdles in Gene Therapy for Hearing Loss
Full Interview Summary: Regeneron envisions DB-OTO reshaping the standard of care for hearing loss by shifting from symptomatic management with prostheses, such as hearing aids and cochlear implants, ...
Manufacture and sale of Cochlear implant systems.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results